Back to search
FDAFDA · Food and drugs·Recall number D-0473-2022

Ephedrine Plus (Ephedrine HCl 25mg, Guaifenesin 200mg) tablets, 24-count bottles, Marketed by: DMD Pharmaceuticals A Division of Dickery Consumer Products, Inc. Noblesville, IN 46060, NDC 65193-320-24

Published February 9, 2022 · Recall initiated: January 24, 2022

Summary

FDA records drug Class II recall D-0473-2022, published February 9, 2022 and initiated January 24, 2022. Recalling firm: Ultra Seal Corporation; Status: Terminated; Reported quantity: 301,842 bottles; Lot: Lot#: 18M063, Exp. Date 01/2022; 19G076, Exp. Date 09/2022. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

cGMP deviations

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Ultra Seal Corporation
Distributor
Nationwide within the United States
Lot
Lot#: 18M063, Exp. Date 01/2022; 19G076, Exp. Date 09/2022
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Ephedrine Plus (Ephedrine HCl 25mg, Guaifenesin 200mg) tablets, 24-count bottles, Marketed by: DMD Pharmaceuticals A Division of Dickery Consumer Products, Inc. Noblesville, IN 46060, NDC 65193-320-24 recalled?

Yes. FDA published recall D-0473-2022 on February 9, 2022. Reported hazard: cGMP deviations

What should I do if I have this product?

Voluntary: Firm initiated · Letter